GGI RapidNews R&D Product Development eZine: Volume
2, Issue 10- December 7, 2001
Robert G. Cooper, in an article for the Journal of Product Innovation Management* discusses the above theme, asks why we repeat our NPD mistakes with such frequency and makes the following points:
Dr. Cooper suggests that many factors differentiating project success from failure are controllable and actionable. He describes eight common denominators of successful NPD projects:
More often than not, teams and management know what has to be done to build a successful project, but simply do not do it! Dr. Cooper describes this as a "quality crisis" in the execution of NPD processes. He suggests that the NPD process is broken. We turn blind to what we know builds success! Why? Dr. Cooper describes seven "blockers," which prevent teams from seeing what produces success:
Dr. Cooper describes these "blockers" in detail and offers numerous solutions for each. He concludes that we know the ABCs of NPD success, but these "blockers" make them invisible. He integrates the various solutions proposed to the above "blockers" into 11 actionable items for NPD success:
* "From Experience: The Invisible Success Factors in Product Innovation" Robert G. Cooper, JPIM, Volume 16, Number 2, March 1999, p. 115-133.
& SOFTWARE REVIEWS
Security stealth concerns aside, the history of systems-on-a-chip, labs-on-a-chip, noses-on-a-chip, MEMS (microelectromechanical systems), MOEMS (micro-opto-electro-mechanical systems), STM (scanning tunneling microscope, which sees atoms), Mechatronics (design subsystems of electromechanical products to ensure optimal system performance) and the the futuristic visions of atomic engineering (nanotechnology, which turns the buildings blocks of matter into microscopic machines) are all grounded in the need for miniaturization. That need arose from the original integrated circuit (IC) invented in 1958. The transistor had been invented 11 years earlier.
Now we are in the process of conceptualizing the transition from millions to billions of transistors on a chip. It is hard to believe that the first microprocessor chip was invented but 30 years ago with the Intel 4004. Electronic "noses" (odor-reactive polymer sensor arrays with pattern recognition systems or artificial neural networks) now can control quality in food processing establishments, make medical diagnoses and do environmental monitoring. From drug delivery systems to monitoring enclosed environments, modern miniaturization is creating new computational possibilities and exciting new markets. International terrorism is simply raising the national security stakes for miniaturization's military applications.
One nanotechnologist has said: "While the human brain has 10 to the 15th power synapses operating effectively with a 1kHz clock frequency at a 0.1% activity level, a silicon multiprocessing unit (MPU) in the year 2011, fabricated using 50 nm (nonometer) line rules, will incorporate 1.4 billion transistors operating with a 10GHz clock frequency at a 1% activity level. The functional throughput of a MPU, defined as the product of the number of gates, the clock frequency, and the activity, is therefore expected to exceed that of the human brain, and yet cost <$1,000 to manufacture, if current cost projections are accurate. These projections are not fanciful; they are grounded in thousands of man-years of physical science research and development, and are simply based on a practical recasting of the MOSFET transistor as a nanotransistor with nanometer-scale dimensions."* Good luck to Garry in round two with "deeper blue."
Little wonder we now see a National Nanotechnology Initiative (NNI). The Initiative was originally created by President Clinton (11/93) under the National Science and Technology Council's (NSTC) Sub-Committee on Nanoscale Science, Engineering and Technology (NSET) to coordinate science, space and technology across government and industry. The NNI now consists of various activities (solicitations for contracts, program reviews and symposia), reports (from government agencies and industry) and R&D support (at various U.S.centers, a technology database and conferences).
See the following links for additional information:
* Solid State Technology "Microelectronics Nanotechnology Future" Pieter "Pete" Burggraaf, page 63-66.
How effective is your organization at planning and executing clinical trials? How good are its protocols? How efficient is patient enrollment? How clean is the data? Pharmaceutical, biotechnology, device, and contract research companies are beginning to think more seriously about how to measure R&D and clinical trial performance. Companies must improve their development performance and R&D metrics offers a way to do so.
On January 28-29, 2002 at the Hyatt Regency in Princeton, NJ, the Institute for International Research (IIR) will present its "How to Measure and Maximize R & D and Clinical Trial Performance with Metrics" conference. Eight good reasons to attend are:
Brad Goldense of GGI will present a newly written paper at the conference on "Improving Productivity and Baseline Performance Using Metrics" in sensor and reagent development.
Please visit http://www.iirusa.com/performancemetrics/index.cfm/Link=1/NewSection=yes
to get additional conference information.